CDK4 EXPRESSION

CDK4及其合作伙伴CDK6是细胞周期进展的关键参与者。该复合物与多种癌症类型有关，是治疗研究和发展的重点。一种针对CDK抑制的靶向治疗是palbociclib，它可能减缓晚期乳腺癌的生长。在小鼠中，CDK抑制可能使突变的PIK3CA肿瘤对PI3K抑制剂敏感。
CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.